Superficial spreading melanoma
Image courtesy of DermNet
Moderna and Merck recently announced follow-up data from the phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study, a clinical trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with pembrolizumab (Keytruda), Merck's anti-PD-1 therapy, in patients with resected high-risk melanoma (stage III/IV) following complete resection. After a follow-up of 3 years, adjuvant treatment with V940 plus pembrolizumab continued to demonstrate a clinically meaningful improvement in recurrence-free survival (RFS), reducing the risk of recurrence or death by 49% (HR=0.510 [95% CI, 0.288-0.906]; one-sided nominal p=0.0095) compared with pembrolizumab alone. V940 plus pembrolizumab also continued to demonstrate a meaningful improvement in distant metastasis-free survival (DMFS), compared with pembrolizumab alone, reducing the risk of developing distant metastasis or death by 62% (HR=0.384 [95% CI, 0.172-0.858]; one-sided nominal p= 0.0077).
Based on data from the phase 2b KEYNOTE-942/mRNA-4157-P201 study, the FDA and European Medicines Agency granted Breakthrough Therapy Designation and the Priority Medicines (PRIME) scheme, respectively, for V940 plus pembrolizumab for the adjuvant treatment of patients with high-risk melanoma.
"As we continue to follow participants in the KEYNOTE-942/mRNA-4157-P201 study, we are excited to see such a robust clinical benefit with mRNA-4157 (V940) as adjuvant treatment in combination with KEYTRUDA in people with resected high-risk melanoma," said Kyle Holen, MD, the senior vice president and head of development of therapeutics and oncology at Moderna, in the news release. "These data add another positive analysis to the multiple endpoints and subgroups previously assessed in this study. Importantly for this technology, the KEYNOTE-942/mRNA-4157-P201 study was the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial and the first combination therapy to show a significant benefit over KEYTRUDA alone in adjuvant melanoma. We look forward to sharing these data with people impacted by this disease and the broader scientific community."
Adverse events observed with V940 in KEYNOTE-942 are similar to those previously reported. At a median planned follow-up of approximately 3 years, the number of patients reporting treatment-related grade 3 adverse events was similar between the arms (25% for V940 plus pembrolizumab vs 20% for pembrolizumab alone). The most common adverse events associated with V940 were fatigue (60.6%), injection site pain (56.7%), and chills (49%).
In July 2023, Moderna and Merck announced the initiation of a pivotal phase 3 randomized INTerpath-001 (NCT05933577) clinical trial evaluating V940 plus pembrolizumab, as an adjuvant treatment in patients with resected high-risk (Stage IIB-IV) melanoma. Global recruitment in INTerpath-001 has started.
"We are committed to driving research forward for innovative modalities in earlier stages of cancer, where we can make the most meaningful impact for patients, by combining Merck's expertise in immuno-oncology with Moderna's innovative mRNA technology," said Marjorie Green, MD, the senior vice president and head of late-stage oncology and global clinical development at Merck Research Laboratories, in the news release. "We are pleased to see the results from this planned analyses on recurrence-free survival for V940 (mRNA-4157), and look forward to working with Moderna in expanding our clinical development program for the individualized neoantigen therapy."
Reference
Moderna and Merck announce mRNA-4157 (v940) in combination with Keytruda(r) (pembrolizumab) demonstrated continued improvement in recurrence-free survival and distant metastasis-free survival in patients with high-risk stage iii/iv melanoma following complete resection versus Keytruda at three years. News release. Moderna. December 14, 2023. Accessed December 18, 2023. https://investors.modernatx.com/news/news-details/2023/Moderna-And-Merck-Announce-mRNA-4157-V940-In-Combination-with-KeytrudaR-Pembrolizumab-Demonstrated-Continued-Improvement-in-Recurrence-Free-Survival-and-Distant-Metastasis-Free-Survival-in-Patients-with-High-Risk-Stage-IIIIV-Melanoma-Following-Comple/default.aspx
Read the rest here:
- American Academy of Dermatology Association Statement on Reports on Counterfeit Injectables - Newswise - April 15th, 2024 [April 15th, 2024]
- Surface Area of IL-23's Epitope Influences Short- and Long-Term Responses for IL-23 Inhibitors in Plaque Psoriasis - Dermatology Times - April 15th, 2024 [April 15th, 2024]
- Atopic Dermatitis (Eczema): 5 Top Self-Care Tips - Everyday Health - April 15th, 2024 [April 15th, 2024]
- Derm In The News: April 7-13 - Dermatology Times - April 15th, 2024 [April 15th, 2024]
- Generative models improve fairness of medical classifiers under distribution shifts - Nature.com - April 15th, 2024 [April 15th, 2024]
- A 30-Year-Old White Female Presented With a 4-Month History of Scaly, Erythematous Patches and Plaques on Her ... - MDedge - April 15th, 2024 [April 15th, 2024]
- 9 Best Baby Eczema Creams of 2024 to Soothe Delicate Skin, According to Dermatologists - Allure - April 15th, 2024 [April 15th, 2024]
- QUIZ: Test Your Knowledge of Rosacea Etiology, Types, and Triggers - Dermatology Times - April 15th, 2024 [April 15th, 2024]
- Empowering Patients: Effective Dermatologic Treatment Selection for Hand and Feet AD - Dermatology Times - April 15th, 2024 [April 15th, 2024]
- How To Treat Strawberry Legs, According To Dermatologists - Women's Health - April 15th, 2024 [April 15th, 2024]
- Rosacea Awareness Month: Resources to Share With Your Patients - Dermatology Times - April 15th, 2024 [April 15th, 2024]
- Understanding Drug Interactions in Systemic Treatment: Impact on Atopic Dermatitis Symptoms - Dermatology Times - April 15th, 2024 [April 15th, 2024]
- Derm In The News: March 31-April 6 - Dermatology Times - April 7th, 2024 [April 7th, 2024]
- Dr. Hillary Johnson-Jahangir of Forefront Dermatology Designated as a Candela Center of Excellence - PR Newswire - April 7th, 2024 [April 7th, 2024]
- How to Boost Your Immune System While Living With Psoriasis - Everyday Health - April 7th, 2024 [April 7th, 2024]
- Im a Harvard-trained dermatologist Ive followed 3 anti-aging rules for years, Im still a fan of a drug... - The US Sun - April 7th, 2024 [April 7th, 2024]
- Cosmetic Procedures for Psoriasis: Are They Safe? - Everyday Health - April 7th, 2024 [April 7th, 2024]
- FDA Approves Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum - Dermatology Times - January 8th, 2024 [January 8th, 2024]
- Dermatology treatments can become an expensive ongoing cost. - The Mountaineer - January 8th, 2024 [January 8th, 2024]
- Dermatology treatments can become an expensive ongoing cost. - Islander News.com - January 8th, 2024 [January 8th, 2024]
- How To Get Rid Of Dark Spots On Your Face, Per Dermatologists - Women's Health - January 8th, 2024 [January 8th, 2024]
- POLL: What Are Your 2024 Dermatology Resolutions? - Dermatology Times - January 8th, 2024 [January 8th, 2024]
- Dermatology treatments can become an expensive ongoing cost. - NBC Right Now - January 8th, 2024 [January 8th, 2024]
- Common perianal diseases and dermatology oddities - DVM 360 - January 8th, 2024 [January 8th, 2024]
- How To Keep Skin Hydrated And Protected In The Cold According To Dermatologists - Essence - January 8th, 2024 [January 8th, 2024]
- Retinol and Retinoids: 9 Things You Should Know Before Using - Vogue - January 8th, 2024 [January 8th, 2024]
- Dermatology treatments can become an expensive ongoing cost. - pdclarion.com - January 8th, 2024 [January 8th, 2024]
- 8 Wintertime Skin Conditions to Look Out For - Health.com - January 8th, 2024 [January 8th, 2024]
- 9 Tips for Common Winter Skin Conditions, According to a Celeb Dermatologist - PEOPLE - January 8th, 2024 [January 8th, 2024]
- FDA Approval of ZELSUVMI Berdazimer Gel: A Revolutionary Achievement | Health News - Medriva - January 8th, 2024 [January 8th, 2024]
- Revolutionary Research Towards Acne Vaccine and Gene Editing Treatments - Medriva - January 8th, 2024 [January 8th, 2024]
- Dermatology treatments can become an expensive ongoing cost. - Corydon Times - January 8th, 2024 [January 8th, 2024]
- Dermatology treatments can become an expensive ongoing cost. - Hometown Register - January 8th, 2024 [January 8th, 2024]
- Rice Water for Hair Growth: Does It Really Work? - Health.com - January 8th, 2024 [January 8th, 2024]
- Dermatology Times 2023 In Review: NP and PA News - Dermatology Times - December 31st, 2023 [December 31st, 2023]
- Colorado dermatology company warning about cybersecurity threat where hacker gained access to health information - Summit Daily - December 31st, 2023 [December 31st, 2023]
- Reviewing the Top Dermatology Headlines of 2023 - Dermatology Times - December 31st, 2023 [December 31st, 2023]
- Dermatology Times 2023 In Review: Acne - Dermatology Times - December 31st, 2023 [December 31st, 2023]
- Skin to Skin: Getting to know UMs new dermatology club - The Miami Hurricane - December 22nd, 2023 [December 22nd, 2023]
- Advancements in Atopic Dermatitis: Insights from the 2024 Masterclasses in Dermatology Conference - Dermatology Times - December 22nd, 2023 [December 22nd, 2023]
- Schweiger Dermatology Group Acquires New Jersey Practices of NavaDerm Partners in Millburn and Englewood Cliffs - PR Newswire - December 22nd, 2023 [December 22nd, 2023]
- Spike in dermatology visits for skin problems seen during summer of wildfires - Medical Xpress - December 22nd, 2023 [December 22nd, 2023]
- More Images of Patients With Psoriasis Are Needed in Published Studies - Dermatology Times - December 22nd, 2023 [December 22nd, 2023]
- Case Based Roundtables Part 2: Valorizing Topical Treatment Options for Patients With Vitiligo - Dermatology Times - December 22nd, 2023 [December 22nd, 2023]
- Practical Approaches to Atopic Dermatitis: Real-World Case Analyses - Dermatology Times - December 22nd, 2023 [December 22nd, 2023]
- Schweiger Dermatology Group Expands into South Florida with Locations in West Palm Beach and Miami Beach - Tullahoma News and Guardian - December 22nd, 2023 [December 22nd, 2023]
- Receding Hairline: Symptoms, Causes, Treatments - Men's Health - December 22nd, 2023 [December 22nd, 2023]
- Podcast CE: Ophytrium in Dermatology: When, where and whys of using Douxo S3 topical therapies - DVM 360 - December 22nd, 2023 [December 22nd, 2023]
- POLL: Which Skin Cancer Drug Recently Received a Complete Response Letter From the FDA? - Dermatology Times - December 22nd, 2023 [December 22nd, 2023]
- How to Treat Textured Skin, According to Dermatologists - Prevention Magazine - December 22nd, 2023 [December 22nd, 2023]
- Dermatology decoded with Dr. Davin Lim - manilastandard.net - December 22nd, 2023 [December 22nd, 2023]
- Arcutis' Zoryve bags 2nd FDA nod, this time as a foam to treat 'the great neglected disease in dermatology' - FiercePharma - December 22nd, 2023 [December 22nd, 2023]
- From customised vitamin infusions to tech-driven dermatology: Skincare trends that dominated 2023 - The Indian Express - December 22nd, 2023 [December 22nd, 2023]
- Aptar Digital Health and Legit.Health Partner to Improve Patient Experience in Immuno-Dermatology - Healthcare Packaging - December 22nd, 2023 [December 22nd, 2023]
- Navigating Location Specific Treatment Selection and Topical Therapy Limitations - Dermatology Times - December 22nd, 2023 [December 22nd, 2023]
- POLL: What Percent of the Global Population is Estimated to Have ... - Dermatology Times - November 18th, 2023 [November 18th, 2023]
- Purple Heart Project Seeks to Provide Veterans With Access to ... - Dermatology Times - November 18th, 2023 [November 18th, 2023]
- Dermatology expert stresses importance of cytology and cultures - DVM 360 - November 18th, 2023 [November 18th, 2023]
- Shawn Kwatra, MD, Shares Highlights From the 12th World ... - Dermatology Times - November 18th, 2023 [November 18th, 2023]
- The Weekly Roundup: November 12-17 - Dermatology Times - November 18th, 2023 [November 18th, 2023]
- Almirall, Absci Partner to Develop AI-Designed Therapies for ... - Dermatology Times - November 18th, 2023 [November 18th, 2023]
- The Skin of Color Society Kicks Off a Season of Giving with its My ... - PR Newswire - November 18th, 2023 [November 18th, 2023]
- Clascoterone Cream in Patients With Acne: New Long-Term Data - Medpage Today - November 18th, 2023 [November 18th, 2023]
- Discovery of hemoglobin in the epidermis sheds new light on our ... - EurekAlert - November 18th, 2023 [November 18th, 2023]
- Global Assessment of Quality of Care for Patients With Malignant ... - Dermatology Advisor - November 18th, 2023 [November 18th, 2023]
- Effective Therapies for Atopic Dermatitis: Expert Recommendations ... - HealthDay - November 18th, 2023 [November 18th, 2023]
- Nonablative Lasers Offer a Gentle Approach to Healthy Skin - Dermatology Times - November 18th, 2023 [November 18th, 2023]
- Aging, Acne, and the Armamentarium: Hot Topics From the Science ... - Dermatology Times - November 18th, 2023 [November 18th, 2023]
- Prior Treatment Options and Outcomes for SD - MD Magazine - November 18th, 2023 [November 18th, 2023]
- Consequences of Lying on the Witness Stand: Are There Any for Dermatology Expert Witnesses? - Dermatology Times - October 27th, 2023 [October 27th, 2023]
- The Cutaneous Manifestations of Drug Reactions Can Mimic Traumatic Injuries: Case Reports and the Potential Role ... - Cureus - October 27th, 2023 [October 27th, 2023]
- Robyn Siperstein, MD, FAAD: Initiating a Patient-First Dialogue in ... - Dermatology Times - October 27th, 2023 [October 27th, 2023]
- Tralokinumab May Improve 52-Week Outcomes in Patients With Moderate to Severe Atopic Dermatitis - Dermatology Advisor - October 27th, 2023 [October 27th, 2023]
- How to Safely and Effectively Exfoliate Your Skin, According to Dermatologists - Allure - October 27th, 2023 [October 27th, 2023]
- Enhancing the Patient Experience Through Addressing Pain Points ... - Dermatology Times - October 27th, 2023 [October 27th, 2023]
- Global Dermatology Collaboration and Licensing Deals and Agreements Analysis Report 2023 with Directory of Dermatology Deal Records Signed Since 2016... - October 27th, 2023 [October 27th, 2023]
- UNION therapeutics to present at 7th Annual Dermatology Drug ... - PR Newswire - October 27th, 2023 [October 27th, 2023]
- Tareen Dermatology Expands to Hudson, Wisconsin, Adding Sixth Location within the Hudson Medical Center - Yahoo Finance - October 27th, 2023 [October 27th, 2023]
- 4 Tips and Considerations for Selecting a Systemic Treatment for ... - Dermatology Times - October 27th, 2023 [October 27th, 2023]
- Yales Richard Edelson on what got him started in research for ... - The Cancer Letter - October 27th, 2023 [October 27th, 2023]